menu search

Protalix undervalued on chmp recommendation of prx-102 for fabry disease

Protalix and chiesi received a CHMP nod for PRX-102 (pegunigalsidase alfa). There is also an FDA PDUFA ...

February 26, 2023, 6:52 am

Acquisition of amryt pharma: how to profit from orphan drugs developers

Amryt Pharma plc will be acquired by chiesi Farmaceutici S.p.A. Amryt Pharma is valued at $1.25 billion...

January 12, 2023, 1:52 pm

chiesi group joins biden administration pledge to decarbonize health care sector, make facilities resilient to climate change

chiesi Group’s leadership recognized by Administration officials at COP27 CARY, N.C., Nov. 10, 2022 (...

November 10, 2022, 2:28 pm

Protalix shares surge after encouraging topline data from another fabry disease trial

Protalix BioTherapeutics Inc (NYSE: PLX) and chiesi Global Rare Diseases, a unit of ...

April 4, 2022, 12:22 pm

Protalix bio, chiesi release final results from late-stage prx-102 trial in fabry disease

Protalix BioTherapeutics Inc (NYSE: PLX) and chiesi Global Rare Diseases, a unit of ...

March 18, 2022, 10:09 am


Search within

Pages Search Results: